CLINICAL_TRIALS trial_result · 2020-11-23

Clinical Trial Update: A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) [Phase 3]

Phase 3 trial evaluating pazopanib as adjuvant treatment for localized renal cell carcinoma has completed (results posted in 2020).

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Cell Carcinoma (RCC), Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-11-23